Sun Pharma stock inches up after getting US FDA nod to review ILUMYA for new arthritis useSun Pharma stock inches up after getting US FDA nod to review ILUMYA for new arthritis use

Introduction

Leading pharmaceutical company receives US FDA acceptance for ILUMYA application for psoriatic arthritis, with regulatory decision expected by October 29 2026 based on Phase 3 studies.

Also Read: Jindal Stainless stock tumbles as company flags production impact amid Middle East war crisis

Share price movement of Sun Pharma

On March 17, 2026, Sun Pharmaceutical Industries Limited opened at ₹1,792.00, up 0.53% from its previous close of ₹1,782.55. The stock reached a high of ₹1,799.70 (0.96%) and a low of ₹1,781.20. By 10:28 AM, it traded at ₹1,791.00, a 0.47% increase, with a market cap of ₹4,29,710.77 crore.

Sun Pharma ILUMYA FDA Review

Sun Pharmaceutical Industries Limited announced that the US FDA has accepted its supplemental Biologics License Application for ILUMYA to treat adults with active psoriatic arthritis.

The FDA has set a regulatory action date of October 29, 2026. The application is supported by results from INSPIRE-1 and INSPIRE-2 Phase 3 clinical studies.

ILUMYA is already approved for moderate to severe plaque psoriasis. If approved, the drug will expand into psoriatic arthritis, adding a new indication to its existing global approvals.

Stock performance of Sun Pharma for period of 1 week, 6 months, and 1 year

Sun Pharmaceutical Industries Limited delivered a 1-week return of -1.63%, a 6-month return of 8.16%, and a 1-year return of 4.63%.

Also Read: Bajel Projects rallies 14% amid tepid market sentiments after winning massive ₹700 Cr+ EPC contract from MSETCL

Shareholding pattern of Sun Pharma

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	54.50%	54.50%	54.50%
FII	16.10%	16.60%	17.30%
DII	20.80%	20.20%	19.50%
Public	8.60%	8.70%	8.50%
Others	0%	0.00%	0.30%

About Sun Pharma

Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) is India’s largest pharmaceutical company with global presence across generics, innovative medicines, and consumer healthcare in over 100 countries.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs